MRK is the day's most notable downgrade. Analysts cut the pharma giant to Hold, trimming the consensus target to $145.8. That follows a prior $142.5 target. The stock carries a $333bn market cap. Short interest sits at just 1.1% of free float — bears are not piling in.
Retail got a mixed read. Gordon Haskett's Chuck Grom cut TJX from Buy to Hold. His new target is $155. The discount retailer had been a market darling. Mizuho also trimmed its target on LOW to $250 from $280, keeping a Buy rating. Home improvement sentiment is softening heading into autumn.
Travel names picked up fresh optimism. EXPE saw its consensus target rise to $336.2 from $333.9. Short interest at 6.6% of free float shows some lingering scepticism. HC Wainwright started INCY with a Buy at $150, a bold call on the biotech.
Chip names stayed firm. ADI got a target lift to $466. also nudged higher. Both reflect continued confidence in the semiconductor cycle.
TGT rounded out the retail picture with a target bump to $158.9, up from $153.9.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
